ARK Investment Management LLC Has $39.16 Million Position in Personalis, Inc. (NASDAQ:PSNL)

ARK Investment Management LLC reduced its holdings in shares of Personalis, Inc. (NASDAQ:PSNL) by 4.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,775,435 shares of the company’s stock after selling 310,088 shares during the period. ARK Investment Management LLC owned about 9.59% of Personalis worth $39,162,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. Olympiad Research LP acquired a new stake in shares of Personalis during the 4th quarter valued at about $59,000. abrdn plc acquired a new position in Personalis in the fourth quarter valued at about $1,722,000. China Universal Asset Management Co. Ltd. acquired a new position in Personalis in the fourth quarter valued at about $87,000. SG Americas Securities LLC acquired a new position in Personalis in the fourth quarter valued at about $63,000. Finally, Barclays PLC boosted its position in Personalis by 45.4% in the third quarter. Barclays PLC now owns 65,468 shares of the company’s stock valued at $352,000 after buying an additional 20,444 shares in the last quarter. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have commented on PSNL. Needham & Company LLC restated a “buy” rating and issued a $7.25 price target on shares of Personalis in a research report on Wednesday, January 8th. Lake Street Capital boosted their price target on shares of Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright reduced their price target on shares of Personalis from $11.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, January 27th.

Personalis Trading Down 7.4 %

Shares of NASDAQ PSNL opened at $4.23 on Wednesday. Personalis, Inc. has a 1-year low of $1.13 and a 1-year high of $7.20. The company has a market cap of $298.84 million, a PE ratio of -2.52 and a beta of 1.73. The company has a 50-day moving average of $5.43 and a two-hundred day moving average of $5.05.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.